CN104788369A - 双吡啶基苯氧基脂肪酰胺衍生物及其医药用途 - Google Patents
双吡啶基苯氧基脂肪酰胺衍生物及其医药用途 Download PDFInfo
- Publication number
- CN104788369A CN104788369A CN201510113933.6A CN201510113933A CN104788369A CN 104788369 A CN104788369 A CN 104788369A CN 201510113933 A CN201510113933 A CN 201510113933A CN 104788369 A CN104788369 A CN 104788369A
- Authority
- CN
- China
- Prior art keywords
- phenoxy group
- pyridyl
- fat amide
- formula
- nitropyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001408 amides Chemical class 0.000 title claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 8
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 8
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 8
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 7
- 206010022000 influenza Diseases 0.000 claims abstract description 7
- 241000700605 Viruses Species 0.000 claims abstract description 6
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims abstract description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 4
- 239000002911 sialidase inhibitor Substances 0.000 claims abstract description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims abstract description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 40
- 125000004076 pyridyl group Chemical group 0.000 claims description 17
- 241001597008 Nomeidae Species 0.000 claims description 14
- 241000712461 unidentified influenza virus Species 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 9
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 239000011630 iodine Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 229940123424 Neuraminidase inhibitor Drugs 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 10
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 44
- 239000001301 oxygen Substances 0.000 description 23
- 229910052760 oxygen Inorganic materials 0.000 description 23
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 17
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 15
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
- ZULRQGBHWBQPFE-UHFFFAOYSA-N 5-chloro-2-fluoropyridine Chemical compound FC1=CC=C(Cl)C=N1 ZULRQGBHWBQPFE-UHFFFAOYSA-N 0.000 description 8
- 102000005348 Neuraminidase Human genes 0.000 description 6
- 108010006232 Neuraminidase Proteins 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 0 CCN(C(C(C)Oc(cc1)ccc1Oc1ncc(C(F)(F)F)cc1)=O)c1ccc(*)c(C#N)[n+]1 Chemical compound CCN(C(C(C)Oc(cc1)ccc1Oc1ncc(C(F)(F)F)cc1)=O)c1ccc(*)c(C#N)[n+]1 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- -1 alkane acid amides Chemical class 0.000 description 4
- 206010064097 avian influenza Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical class NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 3
- 241000712431 Influenza A virus Species 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WLQRXNQHHSUBOI-UHFFFAOYSA-N CC(C(N(C)c(nc1C#N)ccc1[N+]([O-])=O)=O)Oc(cc1)ccc1Oc(ncc(C(F)(F)F)c1)c1Cl Chemical compound CC(C(N(C)c(nc1C#N)ccc1[N+]([O-])=O)=O)Oc(cc1)ccc1Oc(ncc(C(F)(F)F)c1)c1Cl WLQRXNQHHSUBOI-UHFFFAOYSA-N 0.000 description 1
- QOAXFIGDIVJOTH-UHFFFAOYSA-N CC(C(N(C)c(nc1C#N)ccc1[N+]([O-])=O)=O)Oc(cc1)ccc1Oc1ccc(C(F)(F)F)cn1 Chemical compound CC(C(N(C)c(nc1C#N)ccc1[N+]([O-])=O)=O)Oc(cc1)ccc1Oc1ccc(C(F)(F)F)cn1 QOAXFIGDIVJOTH-UHFFFAOYSA-N 0.000 description 1
- ZRCPTJVVCJIZFG-UHFFFAOYSA-N CCN(C(C(C)Oc(cc1)ccc1Oc(ncc(Cl)c1)c1F)=O)c(nc1C#N)ccc1[N+]([O-])=O Chemical compound CCN(C(C(C)Oc(cc1)ccc1Oc(ncc(Cl)c1)c1F)=O)c(nc1C#N)ccc1[N+]([O-])=O ZRCPTJVVCJIZFG-UHFFFAOYSA-N 0.000 description 1
- KQSGXWUUWBYVQW-UHFFFAOYSA-N CCNc(cc1)nc(NC(C(C)Oc(cc2)ccc2OC2N=CC(Cl)=CC2F)O)c1[N+]([O-])=O Chemical compound CCNc(cc1)nc(NC(C(C)Oc(cc2)ccc2OC2N=CC(Cl)=CC2F)O)c1[N+]([O-])=O KQSGXWUUWBYVQW-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
双吡啶基苯氧基脂肪酰胺衍生物 | 抑制率/% |
N-(6-乙氨基-3-硝基吡啶-2-基)-2-[4-(3-氟-5-氯吡啶-2-氧基)苯氧基]丙酰胺 | 16.25 |
N-乙基-N-(6-氰基-5-硝基吡啶-2-基)-2-[4-(3-氟-5-氯吡啶-2-氧基)苯氧基]丙酰胺 | 13.91 |
N-甲基-N-(6-氰基-5-硝基吡啶-2-基)-2-[4-(5-三氟甲基-3-氯吡啶-2-氧基)苯氧基]丙酰胺 | 13.64 |
N-甲基-N-(6-氰基-5-硝基吡啶-2-基)-2-[4-(5-三氟甲基吡啶-2-氧基)苯氧基]丙酰胺 | 22.52 |
N-乙基-N-(6-氰基-5-硝基吡啶-2-基)-2-[4-(5-三氟甲基吡啶-2-氧基)苯氧基]丙酰胺 | 18.71 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510113933.6A CN104788369B (zh) | 2015-03-17 | 2015-03-17 | 双吡啶基苯氧基脂肪酰胺衍生物及其医药用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510113933.6A CN104788369B (zh) | 2015-03-17 | 2015-03-17 | 双吡啶基苯氧基脂肪酰胺衍生物及其医药用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104788369A true CN104788369A (zh) | 2015-07-22 |
CN104788369B CN104788369B (zh) | 2017-06-06 |
Family
ID=53553608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510113933.6A Active CN104788369B (zh) | 2015-03-17 | 2015-03-17 | 双吡啶基苯氧基脂肪酰胺衍生物及其医药用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104788369B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1845894A (zh) * | 2003-08-21 | 2006-10-11 | 阿斯利康(瑞典)有限公司 | 苯氧乙酸衍生物 |
WO2010108187A2 (en) * | 2009-03-20 | 2010-09-23 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
CN102584690A (zh) * | 2012-01-19 | 2012-07-18 | 上海长恒生物医药科技有限公司 | 吡啶-2-酮类化合物,其制备方法以及所述吡啶-2-酮类化合物的应用 |
-
2015
- 2015-03-17 CN CN201510113933.6A patent/CN104788369B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1845894A (zh) * | 2003-08-21 | 2006-10-11 | 阿斯利康(瑞典)有限公司 | 苯氧乙酸衍生物 |
WO2010108187A2 (en) * | 2009-03-20 | 2010-09-23 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
CN102584690A (zh) * | 2012-01-19 | 2012-07-18 | 上海长恒生物医药科技有限公司 | 吡啶-2-酮类化合物,其制备方法以及所述吡啶-2-酮类化合物的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104788369B (zh) | 2017-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103450176B (zh) | 一类含2-(4-氨基苯基)苯并噻唑萘酰亚胺化合物及其应用 | |
CN107721975A (zh) | 具有抗肿瘤活性的brd4小分子抑制剂、合成方法及其应用 | |
CN106749097B (zh) | 一种6-氯-2-氨基苯并噻唑类衍生物及其制备方法和应用 | |
CN105646394B (zh) | 蒎烷基噻唑衍生物及其合成方法和应用 | |
CN103070868B (zh) | 一种含nh-1,2,3-三氮唑的ido抑制剂及其制备方法 | |
CN104817539A (zh) | 2-苯氧基喹喔啉衍生物及其医药用途 | |
CN108484632A (zh) | 青蒿素-苯胺基喹唑啉类衍生物及其制备方法和应用 | |
CN102731454B (zh) | 去氢木香烃内酯衍生物,其药物组合物及其制备方法和用途 | |
CN104817491A (zh) | N-吡啶基-2-苯氧基脂肪酰胺及其医药用途 | |
CN104788369A (zh) | 双吡啶基苯氧基脂肪酰胺衍生物及其医药用途 | |
CN103450163A (zh) | 吲唑类化合物、其制备方法及其药物用途 | |
CN103864642B (zh) | 大黄酸衍生物及其合成方法和用途 | |
CN105078987A (zh) | 组合物38083001030527及其在抗急性痛风药物中的应用 | |
CN106317049B (zh) | 2-[5-(氮唑-1-基)噻唑-2-亚氨基]-5-亚苄基-4-噻唑啉酮作为na抑制剂的应用 | |
CN105343043A (zh) | 一种组合物及其在抗急性痛风药物中的应用 | |
CN104529905B (zh) | N‑3‑苯并咪唑酰双胺类衍生物及其制备方法与应用 | |
CN105440029A (zh) | 5-(1,2,4-三唑-1-基)-2-苄氨基噻唑衍生物及其作为抗肿瘤药物的应用 | |
CN103396361A (zh) | 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用 | |
CN103450180B (zh) | 2-[4-(苯并噁唑-2-氧基)苯氧基]酰胺的医药用途 | |
CN103880700B (zh) | O-肉桂酰-氟苯水杨酰胺类化合物及其在制备抗宫颈癌药物中的应用 | |
CN103524556B (zh) | 双乙酰大黄酸氨基膦酸酯衍生物及其合成方法和应用 | |
CN105193789A (zh) | 组合物及其在抗急性痛风药物中的应用 | |
CN105287590A (zh) | 一种组合物及其在抗急性痛风药物中的应用 | |
CN105287579A (zh) | 组合物及其在抗急性痛风药物中的应用 | |
CN106562951A (zh) | 一种呋喃类d‑3‑磷酸甘油酸脱氢酶别构抑制剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20150722 Assignee: Yichang shangnord Biomedical Technology Co.,Ltd. Assignor: CHINA THREE GORGES University Contract record no.: X2022980027129 Denomination of invention: Dipyridylphenoxy fatty amide derivatives and their pharmaceutical applications Granted publication date: 20170606 License type: Common License Record date: 20221228 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231215 Address after: 430000, Zone B, Free Trade Bio Innovation Port, No. 777 Guanggu 3rd Road, Donghu New Technology Development Zone, Wuhan City, Hubei Province (Biomedical Platform Inspection and Research Building) Q306-307 Patentee after: Wuhan Xinlai Bokang Biotechnology Co.,Ltd. Address before: 443002 No. 8, University Road, Yichang, Hubei Patentee before: CHINA THREE GORGES University |